Sabine Tejpar
萨比娜·泰扎尔
MD, PhD
Professor of Gastrointestinal Oncology, Head of Molecular Digestive Oncology Group胃肠肿瘤学教授兼分子消化肿瘤学组负责人
👥Biography 个人简介
Prof. Sabine Tejpar is a founding architect of the Consensus Molecular Subtype (CMS) classification of colorectal cancer. Her translational research integrates molecular subtypes, tumor microenvironment biology, and RAS/BRAF biomarker discovery to guide CRC therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CMS Classification of Colorectal Cancer
Co-led the international CRC Subtyping Consortium establishing the four-subtype CMS classification framework, providing a reproducible molecular taxonomy that underpins biomarker-driven treatment development and clinical trial stratification in CRC.
RAS/BRAF Biomarker Validation
Performed foundational translational analyses from CRYSTAL and OPUS trials establishing RAS mutation as a negative predictive biomarker for anti-EGFR therapy, directly informing clinical guidelines and regulatory approvals globally.
Representative Works 代表性著作
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Nature Medicine (2015)
Landmark paper establishing the four CMS subtypes with prognostic and predictive implications for CRC treatment.
Mutant KRAS codon 12 and 13 alleles in patients with metastatic CRC: assessment as prognostic and predictive biomarkers
Journal of Clinical Oncology (2010)
Definitive analysis validating expanded RAS mutations as negative predictors of anti-EGFR therapy benefit in mCRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 萨比娜·泰扎尔 的研究动态
Follow Sabine Tejpar's research updates
留下邮箱，当我们发布与 Sabine Tejpar（UZ Leuven / KU Leuven）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment